Page 2 - Nasdaq Jspr News Today

Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Rating) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totalling 3,670,000 shares, an increase of 20.7% from the March 15th total of 3,040,000 shares. Based on an average daily trading volume, of 2,580,000 shares, the short-interest ratio […]

Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Rating) was the recipient of a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 3,040,000 shares, a decrease of 12.1% from the February 28th total of 3,460,000 shares. Based on an average daily volume of 3,800,000 shares, the […]

Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Rating) was the target of a significant drop in short interest in the month of March. As of March 15th, there was short interest totalling 3,040,000 shares, a drop of 12.1% from the February 28th total of 3,460,000 shares. Based on an average trading volume of 3,800,000 shares, the […]

Jasper Therapeutics (NASDAQ:JSPR – Get Rating) and REGENXBIO (NASDAQ:RGNX – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings. Risk & Volatility Jasper Therapeutics has a beta of 2.01, […]

REDWOOD CITY, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell...

Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Rating) saw a significant decrease in short interest in the month of March. As of March 31st, there was short interest totalling 130,700 shares, a decrease of 30.6% from the March 15th total of 188,400 shares. Based on an average trading volume of 90,300 shares, the short-interest ratio is […]

REDWOOD CITY, Calif., March 25, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on...

Jasper Therapeutics Inc (NASDAQ:JSPR – Get Rating) – Equities research analysts at Oppenheimer lowered their FY2022 EPS estimates for Jasper Therapeutics in a research report issued to clients and investors on Monday, March 21st. Oppenheimer analyst J. Olson now expects that the company will earn ($1.18) per share for the year, down from their previous […]

JSP191 is well tolerated with no treatment-related severe adverse events in 17 subjects with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)...